REPL · Replimune Group, Inc.
The latest filing states the doubt was alleviated.
“As described in the Company's Annual Report on Form 10-K for the year ended March 31, 2026, substantial doubt existed about the Company's ability to continue as a going concern. The conditions that raised substantial doubt have been subsequently alleviated, as the Company raised approximately $141.0 million in net proceeds from an equity offering in August 2026.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $212.62M | $221.18M | $189.45M | $174.96M | $126.53M | $79.55M | $56.75M | $38.76M | $22.17M | $13.52M | $6.94M | |
| $102.02M | — | $72.18M | $59.81M | $50.55M | $38.77M | $23.2M | $17.44M | $8.77M | $5.71M | $2.71M | |
| — | $98.74M | $72.18M | — | — | — | — | — | — | — | — | |
| $3.4M | $3.33M | $3.5M | $2.66M | $2.45M | $2.15M | $1.71M | $533K | $148K | $109K | $122K | |
| $297.74M | $319.92M | $261.63M | $234.77M | $177.08M | $118.31M | $79.96M | $56.2M | $30.95M | $19.23M | $9.65M | |
| -$297.74M | -$319.92M | -$261.63M | -$234.77M | -$177.08M | -$118.31M | -$79.96M | -$56.2M | -$30.95M | -$19.23M | -$9.65M | |
| $180K | $5.43M | $14.8M | $19.39M | $3.08M | $278K | -$915K | $3.57M | $112K | -$473K | $1.94M | |
| — | -$314.49M | -$246.83M | -$215.39M | -$174M | -$118.04M | -$80.87M | -$52.63M | -$30.83M | -$19.7M | -$7.7M | |
| — | -$551K | $468K | $408K | $288K | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$297.01M | -$313.94M | -$247.3M | -$215.79M | -$174.28M | -$118.04M | -$80.87M | -$52.63M | -$30.83M | -$19.7M | -$7.7M | |
| -$295.28M | -$313.99M | -$246.7M | -$216.67M | -$167.58M | -$118.62M | -$80.28M | -$52.55M | -$31.65M | -$17.39M | -$9.14M | |
| USD/shares | -$3.15 | -$3.38 | -$3.07 | -$3.24 | -$2.99 | -$2.26 | -$1.75 | — | — | — | — |
| USD/shares | -$3.15 | -$3.38 | -$3.07 | -$3.24 | -$2.99 | -$2.26 | -$1.75 | — | — | — | — |
| shares | — | 92.8M | 80.56M | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.2M | 4.98M | 4.97M |
| shares | — | 92.8M | 80.56M | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.2M | 4.98M | 4.97M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 282 similar-size Biotechnology companies (of 537 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Reportable Segment | -$319,919,000 | -$261,627,000 | -$234,773,000 |